SCYNEXIS completes phase 1 study of SCY-770 for kidney disease
SCYNEXIS Inc. completed a Phase 1 study of SCY-770, an oral AMPK activator for Autosomal Dominant Polycystic Kidney Disease. The study enrolled 25 healthy participants and found the drug well-tolerated. SCY-770 has Orphan Drug Designation and will advance to a Phase 2 trial in Q4 2026. The drug has been evaluated in 300 participants across multiple trials. The condition has one approved therapy, Jynarque, with $1.5B in 2024 U.S. sales.
How this was made
The 30-second read
Why it matters
The Phase 1 completion provides the first human safety and PK data, a key milestone that can influence valuation and partnership prospects.
Market read
New trial data may trigger short‑term buying interest and longer‑term partnership speculation.
What to watch
Orphan drug designation may attract partnership interest, but funding needs remain high.
Background
SCYNEXIS is a clinical‑stage biotech focused on rare diseases. SCY-770 received orphan drug status for ADPKD.
Ticker impact
SCYNEXIS announced completion of a Phase 1 study of its oral AMPK activator SCY-770 for ADPKD.
likely upward pressure as market prices in favorable safety and PK profile.
Phase 1 safety and PK results are new, favorable, and set the stage for a Phase 2 trial later this year.
Market effects
Adds optimism to the rare‑disease biotech sector and may boost peers developing ADPKD therapies.
Limited to US biotech investors; no broader regional effect.
Modest; primarily relevant to biotech and rare‑disease investors.
Counterpoint
If Phase 2 fails to show efficacy, early hype could reverse quickly.
Key entities
- companySCYNEXIS Inc.
Developer of SCY-770, a potential therapy for ADPKD.
- regulatorU.S. FDA
Granted orphan drug designation for SCY-770.
